Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET

Journal of Nuclear Medicine

Volumn 56, Issue 1, 2015, Pages 133-139

  Shalgunov, Vladimir ^a   Van Wieringen, Jan Peter ^b   Janssen, Henk M ^c   Fransen, P Michel ^c   Dierckx, Rudi A J O ^a   Michel, Martin C ^d   Booij, Jan ^b   Elsinga, Philip H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SyMO Chem   (Netherlands)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

18F; Agonist tracer; Dopamine receptor; PET

Indexed keywords

AMINOMETHYL CHROMANE F 18; FLUORINE 18; RACLOPRIDE; TRACER; UNCLASSIFIED DRUG; 2-((4-FLUOROBENZYLAMINO)METHYL)CHROMAN-7-OL; BENZOPYRAN DERIVATIVE; BENZYLAMINE DERIVATIVE; CHROMAN DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DEFLUORINATION; DRUG BINDING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOCHEMISTRY; RAT; AGONISTS; ANIMAL; BRAIN; CHEMISTRY; CHO CELL LINE; CRICETULUS; DIAGNOSTIC USE; DRUG EFFECTS; HAMSTER; HEK293 CELL LINE; KINETICS; MALE; METABOLISM; PROCEDURES; SCINTISCANNING; SPRAGUE DAWLEY RAT; STEREOISOMERISM; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BENZOPYRANS; BENZYLAMINES; BIOLOGICAL TRANSPORT; BRAIN; CHEMISTRY TECHNIQUES, SYNTHETIC; CHO CELLS; CHROMANS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; HEK293 CELLS; HUMANS; KINETICS; LIGANDS; MALE; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOCHEMISTRY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; STEREOISOMERISM;

EID: 84920454983     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.114.145466     Document Type: Article

References (23)

1. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III- the final common pathway. Schizophr Bull. 2009; 35: 549-562.
2. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999; 26: 171-182.
3. Volkow ND, Fowler JS, Wang G-J, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004; 9: 557-569.
4. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology. 2009; 56: 3-8.
5. Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system. Curr Med Chem. 2006; 13: 2139-2153.
6. Chio CL, Lajiness ME, Huff RM. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol. 1994; 45: 51-60.
7. Sibley DR, De Lean A, Creese I. Anterior pituitary dopamine receptors: demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J Biol Chem. 1982; 257: 6351-6361.
8. Liu IS, George SR, Seeman P. The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase. Brain Res Mol Brain Res. 2000; 77: 281-284.
9. 11C-raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther. 2010; 333: 533-539.
10. 11C-raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab. 2012; 32: 127-136.
11. van Wieringen JP, Booij J, Shalgunov V, Elsinga P, Michel MC. Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386: 135-154.
12. Finnema SJ, Bang-Andersen B, Wikström HV, Halldin C. Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography. Curr Top Med Chem. 2010; 10: 1477-1498.
13. 18F-labeled dopamine D2 and D3 receptor agonist sensitive to dopamine: a preliminary PET study. J Nucl Med. 2014; 55: 1164-1170.
14. Mewshaw RE, Kavanagh J, Stack G, et al. New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore: structure-activity relationships of a series of 2-(aminomethyl)chromans. J Med Chem. 1997; 40: 4235-4256.
15. 2/3 receptors in their high-affinity state. J Med Chem. 2014; 57: 391-410.
16. 2/3-agonist radioligands for PET [abstract]. J Nucl Med. 2013; 54(suppl 2): 1108.
17. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27: 1533-1539.
18. Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol. 1992; 42: 432-438.
19. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010; 30: 46-50.
20. 11C-(1)-4-propyl-3, 4, 4a, 5, 6, 10b-hexahydro-2H-naphtho[1, 2-b][1, 4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem. 2005; 48: 4153-4160.
21. 11C-MNPA. Synapse. 2008; 62: 756-763.
22. 2/3 agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding. Synapse. 2010; 64: 301-312.
23. Skinbjerg M, Seneca N, Liow J-S, et al. Dopamine beta-hydroxylase-deficient mice have normal densities of D2 dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding. Synapse. 2010; 64: 699-703.